Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coeptis Therapeutics Holdings (COEPW) FCF Margin (2021 - 2025)

Coeptis Therapeutics Holdings has reported FCF Margin over the past 2 years, most recently at 195.8% for Q4 2025.

  • Quarterly results put FCF Margin at 195.8% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 631.16% (changed N/A YoY), and the annual figure for FY2025 was 631.16%, changed.
  • FCF Margin for Q4 2025 was 195.8% at Coeptis Therapeutics Holdings, up from 906.42% in the prior quarter.
  • Over the last five years, FCF Margin for COEPW hit a ceiling of 26.3% in Q4 2021 and a floor of 3763.35% in Q1 2025.